Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open-label Study 342 (FREEDOM Study).
Takamichi YamamotoSung Chul LimHirotomo NinomiyaYuichi KubotaWon Chul ShinDong Wook KimDong Jin ShinTohru HoshidaKoji IidaTaku OchiaiRisa MatsunagaHiroyuki HigashiyamaHidetaka HiramatsuJi Hyun KimPublished in: Epilepsia open (2020)
Perampanel monotherapy (4 to 8 mg/d) was efficacious and consistent with the known safety profile up to 26 weeks in patients (≥12 years) with primarily newly diagnosed FOS with or without FBTCS.